News | Radiation Therapy | November 02, 2015

New CyberKnife, TomoTherapy Data Presented at ASTRO 2015

Results from several international studies show excellent treatment outcomes for a wide range of tumor types

Accuray, CyberKnife, TomoTherapy, clinical studies, ASTRO 2015

CyberKnife image courtesy of Accuray

November 2, 2015 — Accuray Inc. announced that studies on the clinical use of the CyberKnife and TomoTherapy systems continue to reinforce the devices' broad-based radiation treatment capabilities. More than 80 studies were presented during poster and oral sessions at the 57th Annual American Society for Radiation Oncology (ASTRO) meeting in October. Some of the studies presented show long-term efficacy and safety with median follow-up exceeding five years.

  • Data from China and Japan show faster treatment times and efficacy with TomoEDGE Dynamic Jaws

A study compared the plan quality and delivery efficiency of TomoHelical using TomoEDGE dynamic jaws to TomoHelical fixed-jaw delivery mode for nasopharyngeal carcinoma treatments. Results showed equivalent plan quality, with dynamic jaws mode providing a more efficient delivery and better sparing of the optic chiasm, pituitary and parotid glands when compared to fixed-jaw delivery mode. Clinicians affiliated with the Hong Kong Sanatorium & Hospital conducted the study.

An evaluation of stereotactic radiation therapy (SBRT) for brain metastases using TomoHelical in dynamic jaws mode found treatment time was reduced by 75 percent using this modality compared to treatment with fixed-jaw delivery mode, and at 12 months follow-up the local control rate was 100 percent. Research was conducted at five Japanese centers.

  • Long-term data (5 plus years) show excellent efficacy with both the CyberKnife and TomoTherapy Systems

Five-year physician-reported toxicity, survival, and relapse-free survival outcomes were reported for patients enrolled in a phase 2 prospective multicenter study evaluating SBRT for organ-confined prostate cancer using the CyberKnife System. The data indicate rates of serious adverse events have been minimal, with intermediate-risk patients experiencing high rates of overall and relapse-free survival. Physician-reported toxicities and relapse-free survival rates compared favorably to other radiation therapy modalities. Seven U.S. hospitals participated in the study, including Swedish Cancer Institute in Seattle, Washington, and Beth Israel Deaconess Medical Center in Boston, Massachusetts.

An additional study of the CyberKnife System for low and intermediate organ-confined prostate cancer showed a high rate of biochemical progression-free survival (95.8 percent and 90 percent for low- and intermediate-risk groups, respectively) with acceptable toxicity at a median follow-up of 84 months. Median prostate specific antigen (PSA) nadir was reached at four years and has remained unchanged for up to eight years, suggesting that the response is durable. Research was conducted at FROS Radiation Oncology and CyberKnife Center.

A study of patients with low, medium, or high-risk prostate cancer demonstrated that hypofractionated radiation therapy delivered using TomoHelical and simultaneous integrated boost (SIB) provides excellent results in terms of both efficacy and toxicity. Patients in all categories treated experienced a high rate of biochemical relapse-free survival and overall survival at five years follow-up, with low rates of acute and late toxicities. Research was conducted at San Raffaele Scientific Institute and Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.

  • Clinical innovation in breast cancer and total marrow irradiation

A study examined the safety and efficacy of an accelerated dose/fractionation schedule delivered using the CyberKnife System after lumpectomy for selected patients with early-stage breast cancer. With a median follow-up of 27 months, all patients remained locally controlled with good to excellent cosmesis and no evidence of disease following treatment. Research was conducted at Winthrop University Hospital, Mineola, New York.

A phase 1-2 dose-escalation study evaluated the use of TomoHelical for total marrow irradiation (TMI) as the sole conditioning regimen for a second autologous stem cell transplant (ASCT) in recurrent leukemia patients. Full-body conformal radiation of the bone marrow enabled clinicians to successfully deliver a total dose of up to 1,800 cGy to the entire bony skeleton without dose-limiting toxicity. Median overall survival and progression-free survival were 3.8 years and 17.4 months, respectively. Research was conducted at the Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Ontario, Canada.

For more information: www.accuray.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning

The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning. Image courtesy of Siemens Healthineers.

News | Computed Tomography (CT) | September 15, 2019
Siemens Healthineers debuted two computed tomography (CT) systems dedicated to radiation therapy (RT) planning at the...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
IBA Dosimetry Releases myQA Machines Software at ASTRO 2019
Technology | Quality Assurance (QA) | September 12, 2019
IBA Dosimetry GmbH announced the launch of the new enhanced myQA Machines 2019 software environment at the upcoming...